AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca beat second-quarter profit forecasts on robust sales of cancer, heart and kidney disease drugs and strong demand ...

AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney ...

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall ...

Calquence, which was approved in the U.S. for chronic lymphocytic leukemia patients in November, was the only product of Acerta, which was acquired by AstraZeneca in a $7 billion deal in 2016.

AstraZeneca Late in the afternoon on the first Friday of April, Andrew Monticelli, an oncologist at Rocky Mountain Cancer Centers, got a phone call from Jeff Sharman, the medical director of ...

AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer by Vandana Singh Benzinga Editor Follow ...

AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

The British drugmaker gained access to Calquence in 2015, thanks to a $4 billion-plus deal with developer Acerta. And to that payoff, AstraZeneca isn’t stopping with MCL.